5.695
Schlusskurs vom Vortag:
$5.76
Offen:
$5.75
24-Stunden-Volumen:
1.49M
Relative Volume:
0.58
Marktkapitalisierung:
$424.44M
Einnahmen:
$20.65M
Nettoeinkommen (Verlust:
$-192.65M
KGV:
-2.1988
EPS:
-2.59
Netto-Cashflow:
$-134.39M
1W Leistung:
+19.77%
1M Leistung:
+9.67%
6M Leistung:
-3.62%
1J Leistung:
-7.06%
Verve Therapeutics Inc Stock (VERV) Company Profile
Firmenname
Verve Therapeutics Inc
Sektor
Branche
Telefon
(978) 501-3026
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie VERV mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VERV
Verve Therapeutics Inc
|
5.695 | 424.44M | 20.65M | -192.65M | -134.39M | -2.59 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.44 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.09 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
615.28 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.55 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
251.15 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2024-04-08 | Eingeleitet | H.C. Wainwright | Buy |
2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
2023-02-01 | Eingeleitet | Cantor Fitzgerald | Neutral |
2022-12-15 | Eingeleitet | Goldman | Sell |
2022-10-06 | Eingeleitet | Credit Suisse | Neutral |
2022-08-25 | Hochstufung | Stifel | Hold → Buy |
2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-09-24 | Eingeleitet | Stifel | Hold |
2021-07-12 | Eingeleitet | Guggenheim | Buy |
2021-07-12 | Eingeleitet | JP Morgan | Neutral |
2021-07-12 | Eingeleitet | Jefferies | Buy |
2021-07-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Why Verve Therapeutics Zoomed 40% Higher This Week - MSN
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - MSN
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha
Verve Therapeutics (VERV) Stock Soars on Positive Trial Results - GuruFocus
Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - MSN
Verve impresses investors with second shot at PCSK9 - BioCentury
Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade - marketscreener.com
Why Verve Therapeutics Is Skyrocketing Today - The Globe and Mail
Guggenheim raises Verve Therapeutics stock target to $24 By Investing.com - Investing.com Canada
Verve stock rises as Cantor Fitzgerald upgrades (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Shakes Market with New Genomic Breakthrough - timothysykes.com
Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral - marketscreener.com
Guggenheim Boosts Price Target for Verve Therapeutics (VERV) to $24 | VERV Stock News - GuruFocus
Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results - insights.citeline.com
Early stage cardio data from Verve bump the stock - BioWorld MedTech
Assessing Verve Therapeutics: Insights From 4 Financial Analysts - Benzinga
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data - Yahoo Finance
This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. - Barron's
Verve shares soar after new gene-editing trial shows no safety concerns - The Boston Globe
Verve Therapeutics: FDA Nod Sparks Stock Surge - timothysykes.com
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose - Benzinga
Verve Therapeutics: A New Era in Cardiovascular Disease Treatment? - RagingBull
Verve’s second swing at gene editing for heart disease shows early promise - BioPharma Dive
Verve Shares Soar After New Gene-Editing Trial Shows No Safety Concerns - Bloomberg.com
Verve Therapeutics Stock Rise: Is It A Turning Point? - timothysykes.com
Verve stock jumps on early-stage trial data (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics' VERVE-102 Gene Editing Therapy Trial Shows Positive Initial Data in Clinical Trial - marketscreener.com
Verve Therapeutics reports promising trial results for cholesterol drug By Investing.com - Investing.com Canada
Verve Therapeutics reports promising trial results for cholesterol drug - Investing.com Australia
Verve Therapeutics stock soars on positive clinical trial results By Investing.com - Investing.com Nigeria
Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - Yahoo
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics LawsuitVERV - ACCESS Newswire
Verve stock gains on FDA fast track tag (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Gets FDA Fast Track Designation for VERVE-102 - MarketScreener
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - The Manila Times
Verve Therapeutics Receives U.S. FDA Fast Track Designation For Verve-102, An In Vivo Base Editing Medicine Targeting Pcsk9 - MarketScreener
Finanzdaten der Verve Therapeutics Inc-Aktie (VERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):